This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2006 Jul 13;355(2):213-5.

doi: 10.1056/NEJMc053610.

EGFR mutations in small-cell lung cancers in patients who have never smoked

Maureen F Zakowski, Marc Ladanyi, Mark G Kris; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group

PMID: 16837691
DOI: 10.1056/NEJMc053610

Case Reports

EGFR mutations in small-cell lung cancers in patients who have never smoked

Maureen F Zakowski et al. N Engl J Med. 2006.

. 2006 Jul 13;355(2):213-5.

doi: 10.1056/NEJMc053610.

Authors

Maureen F Zakowski, Marc Ladanyi, Mark G Kris; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group

PMID: 16837691
DOI: 10.1056/NEJMc053610

No abstract available

PubMed Disclaimer

Similar articles

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF. Shigematsu H, et al. Cancer Res. 2005 Mar 1;65(5):1642-6. doi: 10.1158/0008-5472.CAN-04-4235. Cancer Res. 2005. PMID: 15753357
EGFR mutations and the terminal respiratory unit.
Yatabe Y. Yatabe Y. Cancer Metastasis Rev. 2010 Mar;29(1):23-36. doi: 10.1007/s10555-010-9205-8. Cancer Metastasis Rev. 2010. PMID: 20135199 Review.
Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
Wu CC, Hsu HY, Liu HP, Chang JW, Chen YT, Hsieh WY, Hsieh JJ, Hsieh MS, Chen YR, Huang SF. Wu CC, et al. Cancer. 2008 Dec 1;113(11):3199-208. doi: 10.1002/cncr.23925. Cancer. 2008. PMID: 18932251
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
De Pas TM, Giovannini M, Manzotti M, Trifirò G, Toffalorio F, Catania C, Spaggiari L, Labianca R, Barberis M. De Pas TM, et al. J Clin Oncol. 2011 Dec 1;29(34):e819-22. doi: 10.1200/JCO.2011.36.2251. Epub 2011 Oct 31. J Clin Oncol. 2011. PMID: 22042963 No abstract available.
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA, Johnson BE. Jänne PA, et al. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. doi: 10.1158/1078-0432.CCR-06-0555. Clin Cancer Res. 2006. PMID: 16857820 Review.

See all similar articles

Cited by

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.
Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Waqar SN, et al. J Thorac Oncol. 2016 Sep;11(9):1387-96. doi: 10.1016/j.jtho.2016.05.009. Epub 2016 Jul 9. J Thorac Oncol. 2016. PMID: 27401214 Free PMC article. Review.
Beyond the Frontline: A Triple-Line Approach of Thoracic Surgeons in Lung Cancer Management-State of the Art.
Bottet B, Piton N, Selim J, Sarsam M, Guisier F, Baste JM. Bottet B, et al. Cancers (Basel). 2023 Aug 9;15(16):4039. doi: 10.3390/cancers15164039. Cancers (Basel). 2023. PMID: 37627067 Free PMC article. Review.
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.
Meador CB, Hata AN. Meador CB, et al. Pharmacol Ther. 2020 Jun;210:107522. doi: 10.1016/j.pharmthera.2020.107522. Epub 2020 Mar 6. Pharmacol Ther. 2020. PMID: 32151666 Free PMC article. Review.
Drug Resistance to EGFR Inhibitors in Lung Cancer.
Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. Tetsu O, et al. Chemotherapy. 2016;61(5):223-35. doi: 10.1159/000443368. Epub 2016 Feb 25. Chemotherapy. 2016. PMID: 26910730 Free PMC article. Review.
Managing Resistance to EFGR- and ALK-Targeted Therapies.
Lovly CM, Iyengar P, Gainor JF. Lovly CM, et al. Am Soc Clin Oncol Educ Book. 2017;37:607-618. doi: 10.1200/EDBK_176251. Am Soc Clin Oncol Educ Book. 2017. PMID: 28561721 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

R21 CA115051/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal